Tenax Therapeutics: Millennium reports 3.6% stake
The cover pages report shared voting and dispositive power, with zero sole voting power and zero sole dispositive power.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of Tenax Therapeutics, Inc. (TENX) common stock. Each cover page lists 1,362,730 shares, or 3.6% of the class, with shared voting and shared dispositive power; sole voting and dispositive power are each reported as zero.
The statement says the securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. It also says the disclosure is not, by itself, an admission of beneficial ownership by the reporting persons.
Key Figures
Key Terms
beneficially owned regulatory
investment discretion regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.